First patients dosed in OPTIMAL-e1 Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital ...
MedPage Today on MSN
Recent developments in prostate cancer
Practice-changing perioperative therapy, chemo-free combo for CSPC, reducing cognitive eff ...
As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about navigating treatment option in prostate cancer. Advancements in prostate ...
"Our findings open avenues for biomarkers of therapy response and acquired drug resistance to help guide clinical decisions in individual patients with metastatic prostate cancer throughout the course ...
A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess prostate cancer progression or regression during treatment. With this strong ...
Association of cardiovascular outcomes with GnRH agonist and antagonist therapy in non-metastatic prostate cancer. Addition of 18F-DCFPyL PSMA PET to MRI to avoid unnecessary biopsy in men on active ...
Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine ...
If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...
Extracellular vesicles shed by prostate cancer cells to the bloodstream contain tumor-derived material that can be used as biomarkers of therapy response and resistance in patients with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results